Department of Endocrinology, Shandong Provincial Hospital Affilated to Shandong University, Jinan 250100, Shandong, China.
Department of Endocrinology, Shandong Provincial Hospital Affilated to Shandong University, Jinan 250100, Shandong, China.
Gene. 2018 Nov 15;676:73-78. doi: 10.1016/j.gene.2018.07.014. Epub 2018 Jul 6.
The study aimed to ascertain the correlation between AKR1B1 polymorphism rs759853 and the risk of diabetic retinopathy (DR) through a meta-analysis.
Crude odds ratios (ORs) and the corresponding 95% confidence interval (95% CIs) were calculated to assess the association of AKR1B1 rs759853 polymorphism with DR risk. Stratification analyses were further conducted based on ethnicity, diabetes mellitus (DM) type, Hardy-Weinberg equilibrium (HWE) status, and genotyping method. Heterogeneity was detected by Q test. Sensitivity analysis was implemented to check the robustness of final results. Additionally, Begg's funnel plot and Egger's test were used to evaluate underlying publication bias.
Our meta-analysis ultimately incorporated 21 eligible publications with 22 independent case-control studies. The overall results demonstrated that AKR1B1 rs759853 polymorphism had no association with DR risk under all genetic models. However, after subgroup analysis by DM type, the rs759853 polymorphism was a protective factor against the DR onset in patients with type 1 DM (TT vs. CC: OR = 0.33, 95% CI = 0.17-0.67; TT + CT vs. CC: OR = 0.49, 95% CI = 0.36-0.68; TT vs. CC + CT: OR = 0.48, 95% CI = 0.28-0.83; allele T vs. allele C: OR = 0.56, 95% CI = 0.44-0.72; CT vs. CC: OR = 0.52, 95% CI = 0.37-0.74). Furthermore, subgroup analysis by genotyping method suggested that rs759853 genotyped using MassARRAY assay was significantly correlated with decreased risk of DR under dominate model (TT + CT vs. CC: OR = 0.71, 95%CI = 0.52-0.96).
AKR1B1 polymorphism rs759853 may inhibit the occurrence of DR in patients with type 1 DM.
本研究旨在通过荟萃分析,确定 AKR1B1 多态性 rs759853 与糖尿病视网膜病变(DR)风险之间的相关性。
使用粗比值比(OR)和相应的 95%置信区间(95%CI)评估 AKR1B1 rs759853 多态性与 DR 风险的关联。进一步根据种族、糖尿病类型、哈迪-温伯格平衡(HWE)状态和基因分型方法进行分层分析。使用 Q 检验检测异质性。进行敏感性分析以检查最终结果的稳健性。此外,还使用贝叶斯漏斗图和 Egger 检验评估潜在的发表偏倚。
我们的荟萃分析最终纳入了 21 项符合条件的文献,包含 22 项独立的病例对照研究。总体结果表明,在所有遗传模型下,AKR1B1 rs759853 多态性与 DR 风险无关。然而,按糖尿病类型亚组分析时,rs759853 多态性是 1 型糖尿病患者 DR 发病的保护因素(TT 与 CC:OR=0.33,95%CI=0.17-0.67;TT+CT 与 CC:OR=0.49,95%CI=0.36-0.68;TT 与 CC+CT:OR=0.48,95%CI=0.28-0.83;等位基因 T 与等位基因 C:OR=0.56,95%CI=0.44-0.72;CT 与 CC:OR=0.52,95%CI=0.37-0.74)。此外,按基因分型方法的亚组分析表明,使用 MassARRAY 检测的 rs759853 基因型与显性模型下 DR 风险降低显著相关(TT+CT 与 CC:OR=0.71,95%CI=0.52-0.96)。
AKR1B1 多态性 rs759853 可能抑制 1 型糖尿病患者 DR 的发生。